10.06.2022
Health professionals discussed rehabilitation for patients recovered from COVID-19

Post-COVID symptoms, their frequency and severity may vary depending on the virus strain and illness period. Patients who received intensive treatment are a special group, they are under constant follow-up after discharge. The recovery measures were discussed at the 14th International Congress "Neurorehabilitation-2022".

Referring to WHO data, Oksana Drapkina, academician of the Russian Academy of Sciences, professor, doctor of medical science, chief external specialist in therapy and general medical practice of the Ministry of Health of Russian Federation, honored doctor of the Russian Federation, director of the FSBI “National Medical Research Center for Therapy and Preventive Medicine” of the Ministry of Health of Russian Federation, emphasized that post-COVID symptoms can evolve both in the direction of weakening and exacerbation. At the same time, symptoms clinical course is based on a chronic defect forming in the immune system, which can persist for many years and lead to diseases associated with autoimmune inflammation and disorders in the circulatory system.

Professor noted that after the outbreak of Coronavirus infection, up to 60% of patients report fatigue within a month after recovery. Patients with post-COVID syndrome most often face changes in the nervous system, lungs and heart. Changes in the nervous system most often include disorder of the sleep-wake cycle, insomnia, anxiety-depressive disorder, memory impairment, headache. In addition, the heart muscle is often affected too.

“Coronavirus infects vascular endothelium and has a direct toxic effect. Naturally, their damage changes properties of the blood coagulation system. As a result, there are conditions for microthrombi formation. Venous thromboembolism, tissue hypoxia, and organ ischemia also make their contribution,” said Oksana Drapkina. “That is why one of the key recommendations for patients who recovered from Coronavirus infection is to undergo an in-depth medical examination as part of statutory medical insurance.”

Galina Ivanova, chief external specialist in medical rehabilitation of the Ministry of Health of the Russian Federation, head of medical rehabilitation department of the faculty of additional professional education of Federal State Autonomous Educational Institution of Higher Education of the Pirogov University of the Ministry of Health of the Russian Federation, spoke about the rehabilitation routing scale being used today in Russia. It allows taking into account the degree of limitation of the patient's life activity and the conditions for providing a patient with rehabilitation assistance (outpatient, day hospital, round-the-clock medical supervision), as well as the medical rehabilitation stages.

“Two months after a Coronavirus infection, patients have a wide variety of symptoms. These can be represented by manifestations of the central nervous system associated conditions - headache, loss of smell, swallowing dysfunction, severe muscle weakness, anxiety, depression, cognitive impairment. Such patients should be referred for neurorehabilitation. People with musculoskeletal disorders are candidates for orthopedic rehabilitation. Those who have a cardiorespiratory system lesion are treated in general rehabilitation department,”
— commented Galina Ivanova

“One of the serious post-COVID syndrome consequences is an acute lung injury that also affects cardiovascular system. In some patients with severe forms of post-COVID syndrome, lung changes persist for a long time and the so-called “organizing pneumonia” is formed, which in 9% of cases leads to pulmonary fibrosis”, said Andrey Malyavin, doctor of medical science, professor, chief external pulmonologist of the Ministry of Health of Russian Federation in the Central Federal District. “In this case, it is recommended to use antifibrotic therapy or medicines that prevent the development of pulmonary fibrosis.”

Sergey Babak, professor of the phthisiology and pulmonology department, A.I. Evdokimov Moscow State University of Medicine and Dentistry, shared his findings on pulmonary deficiency that can be observed in those who have been ill even 6-7 months after the acute COVID phase. The ongoing inflammatory process in the lungs at this stage increases vascular permeability, leading to lung swelling, and may contribute to the formation of microthrombi. According to Sergey Babak, even fully recovered patients may experience gross fibrotic changes in the lung tissue. Key role in the development of inflammation, in swelling during the illness, and in subsequent fibrosis development is attributed to excessive accumulation of hyaluronic acid in the lungs. The patient in this clinical condition is in need of pharmaceutical support.

As a well-known example of a medicine with an antifibrotic effect, which helps against scars and adhesions, Sergey Babak cited Longidaza® (active ingredient - Bovhyaluronidase azoximer).

“Hyaluronidase contained in enzyme-based medicines such as Longidaza®, reduces hyaluronic acid excess in the lungs, prevents inflammation, swelling, and scarring acting on damaged tissue without affecting healthy one, which helps restore ventilation,”
— professor noted.

According to the results of the DISSSOLVE [1, 2] study, patients in the medicine group, showed a more pronounced improvement in general physical condition, a decrease in the dyspnea severity, increase in physical activity tolerance, level of capillary blood saturation at rest state, compared with the control group.

According to Galina Ignatova, professor and pulmonologist, the study showed that Bovhyaluronidase azoximer helps to enhance the effectiveness of post-COVID rehabilitation. At the same time, the most pronounced effect of the medicine was observed in severe patients.

Galina Ignatova added that the Longidaza mode of action is based on the ability to easily break down hyaluronic acid reducing its excess thus restoring lung ventilation.

Longidaza® has a high safety profile and is well tolerated by patients; today health professionals propose to include it in guidelines for prevention, diagnosis and treatment of Coronavirus infection.


1 https://clinicaltrials.gov/ct2/show/NCT04645368

2 https://dx.doi.org/10.18565/therapy.2021.10.138–146



Back to the list

© Petrovax
The materials posted on the site are for informational purposes only and are not intended to advertise or promote the manufacturer or medications produced.